Chip Wilson said he was diagnosed with facioscapulohumeral muscular dystrophy (FSHD) Type 2 when he was 32. Now 67, he’s created Solve FSHD to find a cure by the end of 2027. (The Logic)

Talking point: The group has been working on developing a strategic plan, said executive director Eva R. Chin at a press conference. She expects the bulk of the funds, about 60 to 70 per cent, will support biotech and biopharma startups. Solve FSHD plans to invest directly in global companies, and rather than take an equity stake, it will receive a royalty or other form of payment if that company’s tech succeeds. It will put those funds back into the organization. Chin said 30 per cent will go toward innovation, which the group expects to take the form of an award like Elon Musk’s XPrize. The organization is complex, Wilson said, “and we’re putting it together.”